Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (121-130 of 361) with videos related to

Pageof 37
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 15, 2008
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809Mark D Hurwitz, Susan Halabi, San-San Ou, et al.
Blood|June 5, 2008
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionBrian Kavanagh, Shaun O'Brien, David Lee, et al.
BJU International|September 8, 2007
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancerEric J Small, Joseph Fontana, Nizar Tannir, et al.
Clinical Genitourinary Cancer|January 21, 2018
Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T ImmunotherapyXiao X Wei, Jaselle Perry, Emily Chang, et al.
European Urology Oncology|May 18, 2019
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate CancerRahul Aggarwal, Xiao Wei, Won Kim, et al.
Cancer|December 6, 2005
A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapyJonathan E Rosenberg, Matthew D Galsky, Nicholas C Rohs, et al.
Prostate Cancer and Prostatic Diseases|May 5, 2019
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)Charles J Ryan, Sandipan Dutta, William K Kelly, et al.
Cancer|September 3, 2005
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group studyUlka N Vaishampayan, James R Faulkner, Eric J Small, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Activities and accomplishments of the cancer and leukemia group B genitourinary committeeEric J Small, Susan Halabi, Phillip Kantoff, et al.
Cancer|June 19, 2009
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCelestia S Higano, Paul F Schellhammer, Eric J Small, et al.
Pageof 37

Showing results (121-130 of 361) with videos related to

Sort By:
Pageof 37
International Journal of Radiation Oncology, Biology, Physics|April 15, 2008
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809Mark D Hurwitz, Susan Halabi, San-San Ou, et al.
Blood|June 5, 2008
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionBrian Kavanagh, Shaun O'Brien, David Lee, et al.
BJU International|September 8, 2007
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancerEric J Small, Joseph Fontana, Nizar Tannir, et al.
Clinical Genitourinary Cancer|January 21, 2018
Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T ImmunotherapyXiao X Wei, Jaselle Perry, Emily Chang, et al.
European Urology Oncology|May 18, 2019
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate CancerRahul Aggarwal, Xiao Wei, Won Kim, et al.
Cancer|December 6, 2005
A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapyJonathan E Rosenberg, Matthew D Galsky, Nicholas C Rohs, et al.
Prostate Cancer and Prostatic Diseases|May 5, 2019
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)Charles J Ryan, Sandipan Dutta, William K Kelly, et al.
Cancer|September 3, 2005
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group studyUlka N Vaishampayan, James R Faulkner, Eric J Small, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Activities and accomplishments of the cancer and leukemia group B genitourinary committeeEric J Small, Susan Halabi, Phillip Kantoff, et al.
Cancer|June 19, 2009
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCelestia S Higano, Paul F Schellhammer, Eric J Small, et al.
Pageof 37